|
|
???tair.name??? >
???browser.page.title.author???
|
"hurvitz s a"???jsp.browse.items-by-author.description???
Showing items 1-12 of 12 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 臺大學術典藏 |
2022-03-10T06:15:00Z |
Matching-adjusted indirect comparison of ribociclib plus fulvestrant versus palbociclib plus letrozole as first-line treatment of hr+/her2? advanced breast cancer
|
Fasching P.A.; Delea T.E.; YEN-SHEN LU; De Boer R.; Hurvitz S.A.; Moynahan A.; Chandiwana D.; Lanoue B.; Hu H.; Thuerigen A.; O��shaughnessy J. |
| 國立成功大學 |
2022 |
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
|
Cort�s, J.;Kim, S.-B.;Chung, W.-P.;Im, S.-A.;Park, Y.H.;Hegg, R.;Kim, M.H.;Tseng, L.-M.;Petry, V.;Chung, Chung C.-F.;Iwata, H.;Hamilton, E.;Curigliano, G.;Xu, B.;Huang, C.-S.;Kim, J.H.;Chiu, J.W.Y.;Pedrini, J.L.;Lee, C.;Liu, Y.;Cathcart, J.;Bako, E.;Verma, S.;Hurvitz, S.A.;Investigators, DESTINY-Breast03 Trial |
| 臺大學術典藏 |
2021-04-26T08:05:28Z |
Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 in patients with metastatic breast cancer: phase II randomized, placebo-controlled study
|
CHIUN-SHENG HUANG; Yu A.L.; Tseng L.-M.; Chow L.W.C.; Hou M.-F.; Hurvitz S.A.; Schwab R.B.; L Murray J.; Chang H.-K.; Chang H.-T.; Chen S.-C.; Kim S.-B.; Hung J.-T.; Ueng S.-H.; Lee S.-H.; Chen C.-C.; Rugo H.S. |
| 臺大學術典藏 |
2021-03-10T02:36:31Z |
Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ? 2 HER2-directed regimens: Phase III NALA trial
|
Saura C.; Oliveira M.; Feng Y.-H.; Dai M.-S.; Chen S.-W.; Hurvitz S.A.; Kim S.-B.; Moy B.; Delaloge S.; Gradishar W.; Masuda N.; Palacova M.; Trudeau M.E.; Mattson J.; Yap Y.S.; Hou M.-F.; De Laurentiis M.; Yeh Y.-M.; Chang H.-T.; Yau T.; Wildiers H.; Haley B.; Fagnani D.; YEN-SHEN LU; Crown J.; Lin J.; Takahashi M.; Takano T.; Yamaguchi M.; Fujii T.; Yao B.; Bebchuk J.; Keyvanjah K.; Bryce R.; Brufsky A.; NALA Investigators |
| 臺大學術典藏 |
2020-05-25T06:51:46Z |
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|
Franke F; Bardia A; Harbeck N; Hurvitz S.A; Chow L; Sohn J; Lee K.S; Campos-Gomez S; Villanueva Vazquez R; Jung K.H; Babu K.G; Wheatley-Price P; De Laurentiis M; Im Y.-H; Kuemmel S; El-Saghir N; Liu M.-C; Carlson G; Hughes G; Diaz-Padilla I; Germa C; Hirawat S; YEN-SHEN LU; Colleoni M; Im S.-A; Tripathy D; Tripathy D;Im S.-A;Colleoni M;Franke F;Bardia A;Harbeck N;Hurvitz S.A;Chow L;Sohn J;Lee K.S;Campos-Gomez S;Villanueva Vazquez R;Jung K.H;Babu K.G;Wheatley-Price P;De Laurentiis M;Im Y.-H;Kuemmel S;El-Saghir N;Liu M.-C;Carlson G;Hughes G;Diaz-Padilla I;Germa C;Hirawat S;Yen-Shen Lu |
| 臺大學術典藏 |
2020-05-25T06:51:44Z |
Tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) with ribociclib (RIB) in premenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-7 subgroup analysis
|
Bardia A;Campos-Gomez S;Hurvitz S.A;Yen-Shen Lu;Im S.-A;Franke F;Chow L;Wheatley-Price P;Melo Cruz F;Alam J;Kong O;Diaz-Padilla I;Miller M;Tripathy D.; Bardia A; Campos-Gomez S; Hurvitz S.A; YEN-SHEN LU; Im S.-A; Franke F; Chow L; Wheatley-Price P; Melo Cruz F; Alam J; Kong O; Diaz-Padilla I; Miller M; Tripathy D. |
| 臺大學術典藏 |
2020-03-23T07:18:55Z |
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial
|
Fresco R.; Helms H.-J.; Xu J.; Lin Y.G.; Sparano J.; Slamon D.; Beckmann M.W.; Afenjar K.; Campone M.; Boileau J.-F.; Wildiers H.; Stroyakovskiy D.; Harbeck N.; Valero V.; Thompson A.M.; CHIUN-SHENG HUANG; Jung K.H.; Symmans W.F.; Martin M.; Hurvitz S.A.; Hurvitz S.A.;Martin M.;Symmans W.F.;Jung K.H.;Chiun-Sheng Huang;Thompson A.M.;Harbeck N.;Valero V.;Stroyakovskiy D.;Wildiers H.;Campone M.;Boileau J.-F.;Beckmann M.W.;Afenjar K.;Fresco R.;Helms H.-J.;Xu J.;Lin Y.G.;Sparano J.;Slamon D. |
| 臺大學術典藏 |
2020-03-23T07:18:53Z |
Paclitaxel with inhibitor of apoptosis antagonist, LCL161, for localized triple-negative breast cancer, prospectively stratified by gene signature in a biomarker-driven neoadjuvant trial
|
Bardia A.; Bardia A.;Parton M.;Kummel S.;Estevez L.G.;Chiun-Sheng Huang;Cortes J.;Ruiz-Borrego M.;Telli M.L.;Martin-Martorell P.;Lopez R.;Beck J.T.;Ismail-Khan R.;Chen S.-C.;Hurvitz S.A.;Mayer I.A.;Carreon D.;Cameron S.;Liao S.;Baselga J.;Kim S.-B.; Parton M.; Kummel S.; Estevez L.G.; CHIUN-SHENG HUANG; Cortes J.; Ruiz-Borrego M.; Telli M.L.; Martin-Martorell P.; Lopez R.; Beck J.T.; Ismail-Khan R.; Chen S.-C.; Hurvitz S.A.; Mayer I.A.; Carreon D.; Cameron S.; Liao S.; Baselga J.; Kim S.-B. |
| 臺大學術典藏 |
2020-03-23T07:18:46Z |
Potent cell-cycle inhibition and upregulation of immune response with abemaciclib and anastrozole in Neomonarch, phase II neoadjuvant study in HR+/HER2- Breast cancer
|
Slamon D.J.; Hurvitz S.A.;Martin M.;Press M.F.;Chan D.;Fernandez-Abad M.;Petru E.;Rostorfer R.;Guarneri V.;Chiun-Sheng Huang;Barriga S.;Wijayawardana S.;Brahmachary M.;Ebert P.J.;Hossain A.;Liu J.;Abel A.;Aggarwal A.;Jansen V.M.;Slamon D.J.; Hurvitz S.A.; Martin M.; Press M.F.; Chan D.; Fernandez-Abad M.; Petru E.; Rostorfer R.; Guarneri V.; CHIUN-SHENG HUANG; Barriga S.; Wijayawardana S.; Brahmachary M.; Ebert P.J.; Hossain A.; Liu J.; Abel A.; Aggarwal A.; Jansen V.M. |
| 國立成功大學 |
2020 |
Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Phase III NALA trial
|
Saura, C.;Oliveira, M.;Feng, Y.-H.;Dai, M.-S.;Chen, S.-W.;Hurvitz, S.A.;Kim, S.-B.;Moy, B.;Delaloge, S.;Gradishar, W.;Masuda, N.;Palacova, M.;Trudeau, M.E.;Mattson, J.;Yap, Yap Y.S.;Hou, M.-F.;De, Laurentiis M.;Yeh, Yeh Y.-M.;Chang, H.-T.;Yau, T.;Wildiers, H.;Haley, B.;Fagnani, D.;Lu, Y.-S.;Crown, J.;Lin, J.;Takahashi, M.;Takano, Takano T.;Yamaguchi, M.;Fujii, T.;Yao, B.;Bebchuk, J.;Keyvanjah, Keyvanjah K.;Bryce, R.;Brufsky, A.;Investigators, NALA |
| 臺大學術典藏 |
2019 |
Neoadjuvant trastuzumab emtansine and pertuzumab in human epidermal growth factor receptor 2–positive breast cancer: Three-year outcomes from the phase III KristinE study
|
Slamon D.; Thompson A.M.; Fraser Symmans W.; Hurvitz S.A.;Martin M.;Jung K.H.;Chiun-Sheng Huang;Harbeck N.;Valero V.;Stroyakovskiy D.;Wildiers H.;Campone M.;Boileau J.-F.;Fasching P.A.;Afenjar K.;Spera G.;Lopez-Valverde V.;Song C.;Trask P.;Boulet T.;Sparano J.A.;Fraser Symmans W.;Thompson A.M.;Slamon D.; Hurvitz S.A.; Martin M.; Jung K.H.; CHIUN-SHENG HUANG; Harbeck N.; Valero V.; Stroyakovskiy D.; Wildiers H.; Campone M.; Boileau J.-F.; Fasching P.A.; Afenjar K.; Spera G.; Lopez-Valverde V.; Sparano J.A.; Boulet T.; Trask P.; Song C. |
| 臺大學術典藏 |
2018-09-10T18:05:39Z |
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial
|
Martin, M.; Symmans, W.F.; Jung, K.H.; Huang, C.-S.; Thompson, A.M.; Harbeck, N.; Valero, V.; Stroyakovskiy, D.; Wildiers, H.; Campone, M.; Boileau, J.-F.; Beckmann, M.W.; Afenjar, K.; Fresco, R.; Helms, H.-J.; Xu, J.; Lin, Y.G.; Sparano, J.; Slamon, D.; Hurvitz, S.A.; CHIUN-SHENG HUANGet al. |
Showing items 1-12 of 12 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
